Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06475209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Adebrelimab + Apatinib in SCLC Maintenance Therapy

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 26, 2024 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This prospective clinical study aims to evaluate and observe the efficacy and safety of Atezolizumab combined with Apatinib in maintenance therapy for extensive-stage small cell lung cancer using a single-arm trial design. The study is planned to be conducted in Shaanxi Province, China, with an initial target enrollment of 60 patients. The study commenced in February 2024, and recruitment is expected to conclude around December 2025, with the trial anticipated to end by December 2026. Assuming no occurrences such as withdrawal of informed consent by subjects, intolerable adverse drug reactions, or investigator-assessed unsuitability for further participation, each participant's estimated duration of study treatment will continue until radiographically confirmed tumor progression.
Trial Details
NCT Number NCT06475209
Lead Sponsor Tang-Du Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 SCLC
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov